CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 26, 2012--
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to
transforming medicine that transforms lives, today announced that the
United States Patent and Trademark Office has issued to POZEN U.S.
Patent 8,206,741 titled ‘Pharmaceutical Compositions for the Coordinated
Delivery of NSAIDs’. This patent includes claims to pharmaceutical
compositions that contain aspirin and a proton pump inhibitor (PPI).
POZEN’s PA (PPI/aspirin) combination drug candidates are covered under
this patent. The ‘741 patent is the second U.S. patent issued to POZEN
for the coordinated delivery of NSAIDs, but the first in which the
claims are focused on aspirin-based products.
POZEN is creating a portfolio of integrated aspirin therapies - the PA
product platform. The products in the PA portfolio are intended to
significantly reduce GI ulcers and other GI complications compared to
taking aspirin alone.
The first candidates are PA32540, containing 325 mg of aspirin, and
PA8140, containing 81 mg of aspirin. Both products are a
coordinated-delivery tablet combining immediate-release omeprazole (40
mg), a proton pump inhibitor, layered around pH-sensitive aspirin. This
novel, patented product is administered orally once a day and an
indication will be sought for use for the secondary prevention of
cardiovascular disease in patients at risk for aspirin-induced ulcers.
POZEN Inc. is a progressive pharmaceutical company that is transforming
how the healthcare industry addresses unmet medical needs. By utilizing
a unique in-source model and focusing on integrated therapies, POZEN has
successfully developed and obtained FDA approval of two self-invented
products in two years. Funded by these milestone/royalty streams, POZEN
is now creating a portfolio of cost-effective, evidence based integrated
aspirin therapies designed to enable the full power of aspirin by
reducing its GI damage.
POZEN is currently seeking strategic partners to help maximize the
opportunity for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The
NASDAQ Global Market. For more detailed company information, including
copies of this and other press releases, please visit www.pozen.com.
Statements included in this press release that are not historical in
nature are “forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act of
1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements, which
are based on current market data and research (including third party and
POZEN sponsored market studies and reports), management’s current
expectations and are subject to a number of risks and uncertainties,
including, but not limited to, our failure to successfully commercialize
our product candidates; costs and delays in the development and/or FDA
approval of our product candidates, including as a result of the need to
conduct additional studies, or the failure to obtain such approval of
our product candidates, including as a result of changes in regulatory
standards or the regulatory environment during the development period of
any of our product candidates; uncertainties in clinical trial results
or the timing of such trials, resulting in, among other things, an
extension in the period over which we recognize deferred revenue or our
failure to achieve milestones that would have provided us with revenue;
our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary
for the development, manufacture, commercialization, marketing, sales
and distribution of any products, including our dependence on
AstraZeneca for the sales and marketing of VIMOVO™; competitive factors;
our inability to protect our patents or proprietary rights and obtain
necessary rights to third party patents and intellectual property to
operate our business; our inability to operate our business without
infringing the patents and proprietary rights of others; general
economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events, including those discussed herein and in
our Quarterly Report on Form 10-Q for the period ended March 31, 2012.
We do not intend to update any of these factors or to publicly announce
the results of any revisions to these forward-looking statements.
Source: POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
Manager, Investor Relations & Public